Daniel J.B. Clarke, et al, published “Gene set predictor for post-treatment Lyme disease” in Cell Reports Medicine on November 15, 2022. The researchers enrolled 152 study participants, each with symptoms of post-treatment Lyme disease (PTLD), to analyze their peripheral blood mononuclear cells (PBMCs) with RNA sequencing (RNA-seq). RNA-seq data from 72 individuals with acute Lyme disease and 44 uninfected controls were incorporated to examine variations in differential gene expression.
Search Results for: treatment
Cherie L. Marvel, et al., published “A multimodal neuroimaging study of brain abnormalities and clinical correlates in post treatment Lyme disease” in PLOS ONE on October 26, 2022. The objective was to uncover evidence that may help to explain the cause of cognitive complaints commonly reported amongst patients with post treatment Lyme disease (PTLD).
Current Problems in Cardiology,(Wang, C., et al.), published “Long-term Outcomes in Treated Lyme Carditis” in *October 2022. Authors provide results of an observational study of post treatment outcomes for 7 […]
In a Brain and Behavior study by Sigurdardottir, A. H., et al, August 26, 2022, researchers looked at fatigue and cognitive impairment after treatment of patients with neuroborreliosis in a […]
Lyme Treatment/Neuro & Psych Symptoms/Severe COVID/Kundalini Yoga/B. Miyamotoi/Lyme Vax Trials/FDA Warning/New Lyme Test/Longhorned Tick/NJ: Send Ticks/TBDWG/COVID Brain/Nebraska/Rickettsia/Kill Ticks
A new study by Richard Horowitz, MD and Phyllis Freeman, MD has been published in Antibiotics that evaluates the efficacy of using short-term, high dose, and pulsed dapsone combination therapy (HDDCT) in the treatment of Chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).
A new study by Richard Horowitz, MD and Phyllis Freeman, MD has been published in Antibiotics that evaluates the efficacy of using short-term high dose pulsed dapsone combination therapy (HDDCT) […]
This study evaluates the effectiveness of tafenoquine (antimalarial primaquine analog) for treatment in an immunocompromised patient infected by a strain of Babesia microti that was partially resistant to both azithromycin and atovaquone treatment.
Results of a new longitudinal, prospective study by Dr. John Aucott, et al. shows that participants with prior Lyme disease(LD) that was diagnosed and treated early were more likely to […]